Healthcare Feb 07, 2023 10:59 AM (GMT+8) · EqualOcean
Biotech company CytoCan (Chinese: 赛德康) announced that it had exceeded the financing target of a CNY 10 million seed funding round, which was led by Forcefield Venture and followed by XtalPi (Chinese: 晶泰科技) and Bopu Capital. Proceeds raised in this round will be used to further develop and optimize AbZed platform technology, expand product pipelines, and accelerate the promotion of clinical studies. Furthermore, proceeds will also be used to support the cooperation with backer XtalPi and utilize XtalPi’s AI technology and CytoCan's AbZed platform to jointly develop the new targeted immunotherapy drug. Its self-developed modular protein technology platform AbZed can design and accurately deliver multi-specific fusion proteins based on targets concerning cancer and other immunotherapy. Now Cy

Source: